Based on randomized controlled trial evidence, it is unclear whether the very modest benefits of antidepressants outweigh their adverse effects in depressed patients with opioid dependence. Low‐quality evidence suggests that antidepressants were no more effective than placebo in reducing depression severity at the end of treatment. At the same time, moderate‐quality evidence shows a greater rate of dropouts due to medical reasons among patients receiving antidepressants, suggesting higher risk of adverse events. Rates of specific adverse events did not differ, however, between antidepressant and placebo groups, but since sample sizes in trials reporting on them ranged from 76 to 131, the studies were likely underpowered to detect smal...
PURPOSE: Recent results suggests the risk of a new onset of depression increases with longer duratio...
BACKGROUND: Depression contributes to persistent opioid analgesic use (OAU). Treating depression may...
Review: antidepressants plus benzodiazepines lead to fewer dropouts and less depression severity at ...
In people with alcohol dependence, naltrexone is an effective and safe treatment to help people to r...
There is insufficient randomized controlled trial evidence to support or refute paroxetine treatment...
Buprenorphine, a partial opioid agonist, has pharmacological features, including safety at overdose ...
Compared with buprenorphine, low‐certainty evidence suggests that dihydrocodeine for detoxification ...
Buprenorphine seems to provide benefits over adrenergic agonists in terms of reduction of withdrawal...
Question: What is the real-world effectiveness of different treatment pathways for opioid use disor...
Compared with unsupervised consumption of a long‐acting opioid substitution medication or routine co...
Alpha2‐adrenergic agonists may be beneficial for controlling symptoms of opioid withdrawal. However,...
QUESTION: In adolescents with major depression, is paroxetine or imipramine more effective than plac...
Purpose: \ud This study aimed to examine the effect of antidepressant use on persistence with newly ...
Objective:Although depression and chronic pain often coexist, few studies have examined antidepressa...
Randomized controlled trials suggest that psychosocial treatments such as contingency management and...
PURPOSE: Recent results suggests the risk of a new onset of depression increases with longer duratio...
BACKGROUND: Depression contributes to persistent opioid analgesic use (OAU). Treating depression may...
Review: antidepressants plus benzodiazepines lead to fewer dropouts and less depression severity at ...
In people with alcohol dependence, naltrexone is an effective and safe treatment to help people to r...
There is insufficient randomized controlled trial evidence to support or refute paroxetine treatment...
Buprenorphine, a partial opioid agonist, has pharmacological features, including safety at overdose ...
Compared with buprenorphine, low‐certainty evidence suggests that dihydrocodeine for detoxification ...
Buprenorphine seems to provide benefits over adrenergic agonists in terms of reduction of withdrawal...
Question: What is the real-world effectiveness of different treatment pathways for opioid use disor...
Compared with unsupervised consumption of a long‐acting opioid substitution medication or routine co...
Alpha2‐adrenergic agonists may be beneficial for controlling symptoms of opioid withdrawal. However,...
QUESTION: In adolescents with major depression, is paroxetine or imipramine more effective than plac...
Purpose: \ud This study aimed to examine the effect of antidepressant use on persistence with newly ...
Objective:Although depression and chronic pain often coexist, few studies have examined antidepressa...
Randomized controlled trials suggest that psychosocial treatments such as contingency management and...
PURPOSE: Recent results suggests the risk of a new onset of depression increases with longer duratio...
BACKGROUND: Depression contributes to persistent opioid analgesic use (OAU). Treating depression may...
Review: antidepressants plus benzodiazepines lead to fewer dropouts and less depression severity at ...